ANRS 0176s OPTICOV

Optimisation of antiviral therapy in immunocompromised Covid-19 patients: a randomised factorial controlled strategy trial

Last updated on 27 February 2024

Primary objective

To assess whether (i) a combination antiviral therapy of two DAA (nirmatrelvir/r + remdesivir) and/or (ii) an increase in nirmatrelvir/r duration from 5 to 10 days improves viral efficacy by decreasing the SARS-CoV-2 positivity rate by real time RT-PCR (CT<32) in nasopharyngeal swabs at D10.

In brief
You are a researcher ?

Theme
Covid-19

Population
Adults

Status
Recruiting

Sample
Nasopharyngeal swabs, Plasma, Serum

Download the study information for researchers

.pdf 1 MB

If you wish to access biological samples from this study:

Samples from the ANRS MIE BioBank are made available after the request is approved either by the Scientific Advisory Board if the study is ongoing, or by the Director of the ANRS MIE if the study has been completed.

For all requests, please fill in the form below and send it to the following address biobanque@anrs.fr

Download the sample request form .pdf 1 MB